Extended Data Table 1 Baseline donor characteristics

From: Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial

  1. Analysis included all randomized patients who received ≥1 dose of study treatment and allo-HSCT.
  2. Baseline was defined as the last measurement on or before the day of the first dose of study treatment (day −1).
  3. allo-HSCT, allogeneic hematopoietic stem cell transplantation; CMV, cytomegalovirus; HLA, human leukocyte antigen.
Back to article page